Orciprenaline
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Orciprenaline: From Bronchial Asthma/Bronchospasm to Obstructive Lung Disease
One-Sentence Summary
Orciprenaline (metaproterenol, DrugBank DB00816) is a non-selective β2-adrenergic agonist historically used as an inhaled bronchodilator for bronchial asthma and airway obstruction. The TxGNN model’s top prediction — Obstructive Lung Disease — largely re-confirms this established pharmacological role rather than identifying a truly novel indication, and is currently supported by 5 clinical trials and 20 publications, though only one trial/publication set directly studies orciprenaline itself rather than related β2-agonists (fenoterol, salbutamol, etc.).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally documented — the drug is unmarketed in India (0 licenses), so no official indication text exists. Literature consistently identifies its historical use as a bronchodilator for bronchial asthma/bronchospasm. |
| Predicted New Indication | Obstructive Lung Disease |
| TxGNN Prediction Score | 99.9953% |
| Evidence Level | L2 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data from DrugBank is currently unavailable (original_moa: Data Gap). Based on the evidence assembled, orciprenaline is a non-selective β2-adrenergic receptor agonist that directly relaxes bronchial smooth muscle — a textbook bronchodilator mechanism that maps directly onto the core pathophysiology of obstructive lung disease (increased airway resistance).
This is not a mechanistically distant repurposing story: multiple retrieved publications (e.g., PMID 8834341, 8341859, 1974678) describe orciprenaline/metaproterenol being directly compared against other β2-agonists (fenoterol, salbutamol, tulobuterol) and anticholinergics in exactly this disease population. In other words, TxGNN’s highest-scoring prediction appears to be substantially rediscovering the drug’s known, established pharmacological class use rather than surfacing a genuinely new therapeutic hypothesis — a useful sanity check on model validity, but weaker as a “new indication” business case.
A caveat: most of the clinical trial evidence retrieved involves comparator drugs (ipratropium, fenoterol, tiotropium) rather than orciprenaline as the study drug itself, so trial-level relevance grading is mixed (B/C), with only the literature directly confirming orciprenaline/metaproterenol’s own efficacy in this population.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01095016 | Phase 3 | Completed | 32 | Open-label, randomized, cross-over trial comparing Meptin® Swinghaler and Berotec N® aerosol in mild-to-moderate stable asthma (Grade B — bronchodilator class trial; orciprenaline not confirmed as study drug). |
| NCT00274066 | Phase 3 | Completed | 65 | Evaluated acute bronchodilator effect of ipratropium and fenoterol vs. placebo on top of tiotropium in COPD (Grade C — comparator drugs, not orciprenaline). |
| NCT01933984 | N/A | Completed | 51 | Individualized vs. fixed dosing of inhaled bronchodilator to reduce airway resistance in intubated COPD patients (Grade B — class-relevant, drug identity unconfirmed). |
| NCT05183841 | N/A | Unknown | 40 | Effect of bronchodilators on exercise capacity in bronchiectasis patients (Grade C — atypical obstructive population, status unknown). |
| NCT00460577 | Phase 4 | Completed | 60 | Randomized double-dummy trial: formoterol vs. nebulized ipratropium+fenoterol in children (5–<12y) with acute bronchial obstruction (Grade C — formoterol-based, indirect evidence). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8834341 | 1996 | RCT | European Respiratory Journal | Double-blind study directly comparing nebulized glycopyrrolate and metaproterenol (orciprenaline), alone and combined, for bronchodilation in stable COPD. |
| 8341859 | 1993 | RCT | Respiration | Double-blind, randomized cross-over trial comparing fenoterol/ipratropium bromide with salbutamol in chronic obstructive lung disease (24 patients). |
| 7345424 | 1981 | Review | Praxis und Klinik der Pneumologie | Review of bronchospasmolytic (bronchodilator) drug classes, covering β-adrenergic agents including orciprenaline. |
| 6142760 | 1983 | Review | Clinical Reviews in Allergy | Review of adrenergic drugs used in obstructive airway disease. |
| 4942356 | 1970 | Review | Medizinische Klinik | Review on allergic bronchial asthma management. |
| 2951816 | 1986 | Cohort | Respiration | Controlled long-term (≥84 day) study of fenoterol + ipratropium bromide aerosol combination in chronic obstructive lung disease. |
| 2879458 | 1987 | Cohort | The American Journal of Medicine | Double-blind ER study (199 patients) of nebulized anticholinergic and sympathomimetic regimens in acute airway obstruction (asthma/COAD). |
| 2951811 | 1986 | Cohort | Respiration | Compared fenoterol-ipratropium combination with terbutaline in chronic obstructive lung disease (ventilatory response, tolerance, side effects). |
| 7701449 | 1995 | Cohort | Thorax | Studied effect of high-dose β2-agonist on mechanical loading and control of breathing in severe COPD. |
| 1974678 | 1990 | Cohort | Lung | Two-month double-blind cross-over study: tulobuterol aerosol vs. fenoterol aerosol in chronic obstructive lung disease (36 patients). |
Safety Considerations
No structured warnings or contraindications data is currently available (Data Gap DG001, flagged Blocking — TFDA/local label PDF has not yet been retrieved and parsed).
Drug Interactions: A DDI query (DDInter, 374 total interactions identified) returned one Major interaction and several Moderate/Minor ones among the sampled results:
| Interacting Drug | Level |
|---|---|
| Dolasetron | Major |
| Acarbose, Isometheptene, Famotidine, Epinephrine, Albiglutide, Alogliptin, Canagliflozin, Metformin, Chlorpropamide, Clarithromycin, Dapagliflozin, Diethylpropion, Dulaglutide | Moderate |
| Hydrocortisone, Triamcinolone, Dexamethasone, Beclomethasone dipropionate, Betamethasone, Budesonide | Minor |
Given 374 total interactions on file, this is only a partial sample — a full DDI screen against the patient’s concomitant medications is required before any clinical use.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic rationale is strong (β2-agonist bronchodilator directly addressing obstructive airway pathophysiology) and is corroborated by one RCT studying orciprenaline/metaproterenol itself (PMID 8834341) plus a body of class-level evidence (L2). However, the drug is unmarketed in India (0 licenses) and formal label safety data (warnings/contraindications) is missing and flagged as a Blocking data gap — this must be resolved before any S1 safety assessment can proceed.
To proceed, the following is needed:
- Retrieve and parse TFDA/local label PDF for warnings, contraindications, and dosing (DG001, Blocking)
- Obtain formal DrugBank MOA record to replace the current Data Gap (DG002)
- Clarify whether any of the 5 retrieved trials actually dosed orciprenaline directly, versus comparator β2-agonists, to firm up the evidence grade
- Full DDI screen against target patient population’s concomitant medications (374 total interactions on file, only 20 sampled here)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.